ATAI Life Sciences N.V.·4

Mar 19, 7:29 PM ET

Johnson Anne Nagengast 4

4 · ATAI Life Sciences N.V. · Filed Mar 19, 2025

Insider Transaction Report

Form 4
Period: 2025-03-14
Johnson Anne Nagengast
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Restricted Stock Units

    2025-03-14100,0000 total
    Common Shares (100,000 underlying)
  • Exercise/Conversion

    Common Shares

    2025-03-14+100,000173,590 total
Footnotes (1)
  • [F1]Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. 50% of the restricted stock units vested on March 14, 2024, the first anniversary of the grant date and 50% vested on March 14, 2025, the second anniversary of the grant date.

Documents

1 file
  • 4
    form4.xmlPrimary

    FORM 4